Tests hyperbaric oxygen after clot removal in stroke from a large blocked vessel
Tests hyperbaric oxygen added to standard care in adults with large-vessel stroke after thrombectomy.
Plain-language title generated from the registry record
Registry title: HBO After Thrombectomy for AIS With LVO
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 80 with a stroke caused by a blocked large brain artery who have had a clot-removal procedure (endovascular treatment). It tests whether hyperbaric oxygen therapy afterwards improves recovery at 90 days.
- Age
- 18 to 80 years
- Sex
- All sexes can join.
- Disease stage
- Acute stroke from a blocked large brain artery (internal carotid artery, middle cerebral artery M1 segment or basilar artery), confirmed on imaging. Stroke onset or last normal time up to 24 hours before the procedure. NIHSS score before the procedure of at least 6 (front of the brain) or at least 10 (back of the brain). ASPECTS or pc-ASPECTS score of at least 6. PMI of 3 or less if the basilar artery is blocked.
- Earlier treatment
- Must have received endovascular treatment (clot removal) following current guidelines.
Main reasons for not taking part
- Pregnant, or positive pregnancy test before randomization
- Known bleeding risks, or severe liver or kidney problems
- Very high blood pressure that medicine cannot control (systolic above 185 mmHg or diastolic above 110 mmHg)
- Cannot take part in hyperbaric oxygen therapy, or has a disease that makes it unsuitable (such as COPD or acute respiratory distress syndrome)
- Taking part in another drug or medical device trial
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07626450, who can take part
Where in China
- Beijing Tiantan HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Beijing Tiantan Hospital
- Trial code
- NCT07626450
- Record updated
- 4 June 2026
- Original description
The purpose of this RCT trial is to evaluate whether the sequential hyperbaric oxygen therapy can improve the 90-day functional outcome in patients with acute large vessel occlusion ischemic stroke after endovascular treatment.Read full original descriptionShow less
HyperBaric Oxygen Therapy After ACute Thrombectomy in Acute Ischemic strOke Due to Large Vessel occlusioN
The purpose of this RCT trial is to evaluate whether the sequential hyperbaric oxygen therapy can improve the 90-day functional outcome in patients with acute large vessel occlusion ischemic stroke after endovascular treatment.
Inclusion: Age 18~80 years; Clinically diagnosed as acute large vessel occlusive ischemic stroke, suitable for and received endovascular treatment according to current clinical guidelines; The onset of stroke or the last normal time to the time of endovascular treatment ≤ 24 hours; Pre-stroke mRS score of 0 or 1; Baseline NIHSS score before endovascular treatment ≥ 6 points in the anterior circulation or ≥10 points in the posterior circulation; CTA, MRA, or DSA angiography before endovascular treatment confirmed occlusion of large vessels (internal carotid artery, middle cerebral artery M1 segment, basilar artery), consistent with symptoms and signs; The corresponding anterior circulation ASPECTS score or posterior circulation pc-ASPECTS score ≥ 6 points; The pontine midbrain index (PMI) of patients with acute basilar artery occlusion ≤3; Patients or their family members sign the informed consent form.
Exclusion: Females of pregnancy, or positive pregnancy test prior to randomization; Participating in other drug or medical device clinical trials; Patients with extensive bleeding or severe increase in infarct area, midline displacement (>0.5cm), etc. during endovascular treatment, who plan to undergo bone valve decompression or ventricular drainage; Severe persistent and medication-uncontrollable hypertension (systolic blood > 185 mmHg or diastolic blood > 110 mmHg); End-stage disease other than the nervous system, life expectancy < 90 days; Patients with anemia, polycythemia or other conditions requiring urgent oxygen; Unable to cooperate with hyperbaric oxygen therapy, or have other diseases that are not suitable for hyperbaric oxygen therapy (such as active/chronic obstructive pulmonary disease, acute respiratory distress syndrome, tension pneumothorax, tension pneumocephalus, etc.); Known bleeding risk factors, including coagulation factor deficiency, or receiving anticoagulant therapy, INR>3.0 or APTT > 3 times normal or platelet count less than 50×10⁹/L; Severe hepatic or renal dysfunction (severe hepatic dysfunction refers to ALT or AST > 3 times the upper limit of the normal range, severe renal dysfunction refers to serum creatinine Cr >1.5 times the upper limit of the normal range); Baseline blood glucose of <50 mg/dL (2.78 mmol/L) or >400 mg/dL (22.20 mmol/L); The oxygen required to maintain 95% of peripheral arterial oxygen saturation (SaO2) under the current medium-term management guidelines > 3L/min; CT or MR suggests intracranial tumors (other than meningiomas) or other high-risk intracranial vascular malformations.